One-year clinical outcome in an unselected patient population treated with the Genous™ Endothelial Progenitor Cell Capturing Stent

Catheterization and Cardiovascular Interventions

Volumn 77, Issue 6, 2011, Pages 809-817

  Klomp, Margo ^a   Beijk, Marcel A M ^a   Tijssen, Jan G P ^a   De Winter, Robbert J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

bioengineered stent technology; endothelial progenitor cell; percutaneous coronary intervention; restenosis

Indexed keywords

CD34 ANTIBODY;

ADULT; AGED; ANTIGEN BINDING; ARTICLE; BARE METAL STENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; ENDOTHELIAL PROGENITOR CELL; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; IATROGENIC DISEASE; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; RISK FACTOR; STENT THROMBOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIGENS, CD34; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETES MELLITUS; ENDOTHELIAL CELLS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MATCHED-PAIR ANALYSIS; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STEM CELLS; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955401255     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22795     Document Type: Article

References (42)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban HE, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780. (Pubitemid 34586912)
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231. (Pubitemid 38067635)
3. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R,. Vascular responses to drug eluting stents. Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27: 1500-1510. (Pubitemid 46986103)
4. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435-2441. (Pubitemid 46717966)
5. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006; 27: 166-170. (Pubitemid 43069032)
6. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202. (Pubitemid 43929240)
7. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW,. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088-2092. (Pubitemid 40814135)
8. Asahara T, Murohara T, Sullivan A, Silver M, van der ZR, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967. (Pubitemid 27087709)
9. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228. (Pubitemid 29377293)
10. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T,. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600. (Pubitemid 36204953)
11. Kawamoto A, Asahara T,. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter Cardiovasc Interv 2007; 70: 477-484. (Pubitemid 47597014)
12. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-2987. (Pubitemid 40814192)
13. Young PP, Vaughan DE, Hatzopoulos AK,. Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog Cardiovasc Dis 2007; 49: 421-429. (Pubitemid 46693946)
14. Kutryk MJ, Kuliszewski MA,. In vivo endothelial progenitor cell seeding for the accelerated endothelialization of endovascular devices. Am J Cardiol 2003; 92: 6A: 94L-95L.
15. Kutryk MJ, Kuliszewski MA,. In vivo endothelial progenitor seeding of stented arterial segments and vascular grafts. Circulation 2003; 108: IV-573.
16. Kutryk MJ, Kuliszewski MA,. The future beyond drug eluting stents: Endothelial cell capture. Int Symp Endovas Therapy 2004;(Course syllabus): 125-129.
17. Aoki J, Serruys PW, van BH, Ong AT, McFadden EP, Sianos G, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: The HEALING-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry. J Am Coll Cardiol 2005; 45: 1574-1579. (Pubitemid 40704488)
18. Duckers HJ, Silber S, de Winter RJ, den Heijer P, Rensing B, Rau M, et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: Evaluation of an endothelial progenitor cell capturing stent. EuroInterv 2007; 3: 67-75.
19. Guidance on the Use of Coronary Artery Stents. Technology Appraisal No. 71 (October 2003) National Institute for Clinical Excellence (NICE).
20. Beijk MA, Klomp M, Verouden NJ, et al. Genous endothelial progenitor cell capturing stent vs. The Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: A randomized, single-centre, pilot study 1. Eur Heart J 2010; 31: 1055-1064.
21. Klomp M, Beijk MA, Verouden NJ, Tijssen JG, de Winter RJ,. Design and rationale of the TRI-stent adjudication study (TRIAS) program 7. Am Heart J 2009; 158: 527-532.
22. Thygesen K, Alpert JS, White HD,. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173-2195. (Pubitemid 350123680)
23. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351. (Pubitemid 46685903)
24. Duckers HJ, Soullie T, den Heijer P, Rensing B, de Winter RJ, Rau M, et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: Final results of the healing II trial using an endothelial progenitor cell capturing stent (Genous R stent)™. EuroInterv 2007; 3: 350-358.
25. Miglionico M, Patti G, D'Ambrosio A, Di SG,. Percutaneous coronary intervention utilizing a new endothelial progenitor cells antibody-coated stent: A prospective single-center registry in high-risk patients. Catheter Cardiovasc Interv 2008; 71: 600-604. (Pubitemid 351550395)
26. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323. (Pubitemid 37186209)
27. Lasala JM, Cox DA, Lewis SJ, et al. Expanded use of the TAXUS express stent: Two-year safety insights from the 7,500 patient ARRIVE Registry programme. EuroIntervention 2009; 5: 67-77.
28. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry 1. Circulation 2006; 113: 1434-1441. (Pubitemid 43739440)
29. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial 1. Lancet 2008; 372: 1163-1173.
30. Lagerqvist B, Carlsson J, Frobert O, et al. Stent thrombosis in Sweden: A report from the Swedish coronary angiography and angioplasty registry 1. Circ Cardiovasc Interv 2009; 2: 401-408.
31. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-589. (Pubitemid 28435240)
32. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-1873. (Pubitemid 29010448)
33. Schofer J, Schluter M, Rau T, Hammer F, Haag N, Mathey DG,. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: A controlled study. J Am Coll Cardiol 2000; 35: 1554-1559. (Pubitemid 30307500)
34. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91: 979-989.
35. de Winter RJ,. The OrbusNeich GENOUS EPC-capture stent clinical trial program; e-HEALING, AMC registry, TRIAS. TCT 2008, Washington USA. 10-13-2008. Abstract.
36. Silber S,. First results of the 1-year follow-up for the endothelial progenitor cells (EPC) capturing genous stent. AHA 2008, New Orleans, USA. 11-9-2008. Abstract.
37. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003; 92: 1049-1055. (Pubitemid 36588505)
38. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057-2064. (Pubitemid 29010476)
39. Dimmeler S, Aicher A, Vasa M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-397. (Pubitemid 32730785)
40. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow - Derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405. (Pubitemid 32730786)
41. Briguori C, Testa U, Riccioni R, et al. Correlations between progression of coronary artery disease and circulating endothelial progenitor cells 276. FASEB J 2010; 24: 1981-1988.
42. Pelliccia F, Cianfrocca C, Rosano G, Mercuro G, Speciale G, Pasceri V,. Role of endothelial progenitor cells in restenosis and progression of coronary atherosclerosis after percutaneous coronary intervention: A prospective study 5, 282. JACC Cardiovasc Interv 2010; 3: 78-86.